RU2009113557A - Фармацевтические композиции для перорального или ректального введения белковых веществ - Google Patents

Фармацевтические композиции для перорального или ректального введения белковых веществ Download PDF

Info

Publication number
RU2009113557A
RU2009113557A RU2009113557/15A RU2009113557A RU2009113557A RU 2009113557 A RU2009113557 A RU 2009113557A RU 2009113557/15 A RU2009113557/15 A RU 2009113557/15A RU 2009113557 A RU2009113557 A RU 2009113557A RU 2009113557 A RU2009113557 A RU 2009113557A
Authority
RU
Russia
Prior art keywords
substances
active agents
composition according
tnfα
cytokines
Prior art date
Application number
RU2009113557/15A
Other languages
English (en)
Russian (ru)
Inventor
Мауро АЯНИ (IT)
Мауро АЯНИ
Луиджи МОРО (IT)
Луиджи МОРО
Роберто ВИЛЛА (IT)
Роберто ВИЛЛА
Original Assignee
Космо Текнолоджиз Лтд (Ie)
Космо Текнолоджиз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20061741 external-priority patent/ITMI20061741A1/it
Priority claimed from ITMI20071205 external-priority patent/ITMI20071205A1/it
Application filed by Космо Текнолоджиз Лтд (Ie), Космо Текнолоджиз Лтд filed Critical Космо Текнолоджиз Лтд (Ie)
Publication of RU2009113557A publication Critical patent/RU2009113557A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2009113557/15A 2006-09-12 2007-09-07 Фармацевтические композиции для перорального или ректального введения белковых веществ RU2009113557A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI20061741 ITMI20061741A1 (it) 2006-09-12 2006-09-12 Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
ITMI2006A001741 2006-09-12
ITMI20071205 ITMI20071205A1 (it) 2007-06-15 2007-06-15 Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche
ITMI2007A001205 2007-06-15

Publications (1)

Publication Number Publication Date
RU2009113557A true RU2009113557A (ru) 2010-10-20

Family

ID=39107203

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009113557/15A RU2009113557A (ru) 2006-09-12 2007-09-07 Фармацевтические композиции для перорального или ректального введения белковых веществ

Country Status (8)

Country Link
US (1) US20100004157A1 (cg-RX-API-DMAC10.html)
EP (1) EP2081555A2 (cg-RX-API-DMAC10.html)
JP (1) JP2010502759A (cg-RX-API-DMAC10.html)
KR (1) KR20090086060A (cg-RX-API-DMAC10.html)
CA (1) CA2663548A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009002756A (cg-RX-API-DMAC10.html)
RU (1) RU2009113557A (cg-RX-API-DMAC10.html)
WO (1) WO2008031770A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
US12203056B2 (en) 2008-03-28 2025-01-21 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
US10946091B2 (en) * 2012-06-04 2021-03-16 Gaurav Agrawal Compositions and methods for treating Crohn's disease and related conditions and infections
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2015176031A2 (en) * 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
AU2016257813B2 (en) 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
EP3294273A4 (en) * 2015-05-08 2018-12-05 Incube Labs, LLC Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3435982A1 (en) * 2016-03-31 2019-02-06 VHsquared Limited Compositions
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CA3045310A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3501503A1 (en) 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ,インク. ポリペプチド
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
AU698393B2 (en) * 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
CN1997352B (zh) * 2004-06-17 2010-12-01 天野酶制品美国有限公司 含粘膜粘附性聚合物的酶、微生物和抗体的控释制剂
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga

Also Published As

Publication number Publication date
US20100004157A1 (en) 2010-01-07
WO2008031770A3 (en) 2008-09-12
KR20090086060A (ko) 2009-08-10
JP2010502759A (ja) 2010-01-28
CA2663548A1 (en) 2008-03-20
EP2081555A2 (en) 2009-07-29
WO2008031770A2 (en) 2008-03-20
MX2009002756A (es) 2009-05-25

Similar Documents

Publication Publication Date Title
JP2010502759A5 (cg-RX-API-DMAC10.html)
CN109152738B (zh) 组合物
JP2022141701A (ja) ブルトン型チロシンキナーゼ阻害剤の薬学的製剤
CN115279376A (zh) 用于治疗异常细胞生长的组合疗法
BR112019018576A2 (pt) métodos de tratamento de doença de crohn e colite ulcerativa
JP2010502759A (ja) タンパク質物質の経口または直腸投与のための医薬組成物
JP2007511529A5 (cg-RX-API-DMAC10.html)
Kumar et al. Gastroretentive dosage forms for prolonging gastric residence time
JP2019529476A5 (cg-RX-API-DMAC10.html)
WO2014190898A1 (zh) 一种异硫氰酸酯类化合物制剂
JP2013527224A (ja) 経口薬物療法のための方法および組成物
ES2870562T3 (es) Composiciones y procedimientos para el tratamiento del crecimiento celular anormal
JP2023536094A (ja) 新規の胃内滞留性持続放出剤形
KR102699072B1 (ko) 항체 및 이의 단편을 사용한 염증성 장 질환의 국소 치료
CN109803684A (zh) 用于治疗肝细胞癌的组合疗法
ES3060895T3 (en) Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
JP7372740B2 (ja) 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
JP2018516937A5 (cg-RX-API-DMAC10.html)
KR20250123210A (ko) Her2 억제제 고체 분산체의 투여 스케줄
Xu et al. Tenosynovial giant cell tumor (TGCT): Mechanisms and advances in targeted treatments
CN101534800A (zh) 用于口服或直肠施用蛋白质物质的药物组合物
Yu et al. Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update
Gidwani et al. Factorial design and a practical approach for gastro-retentive drug delivery system
Welton et al. Colon, Rectum, and Anus
CN121729222A (zh) 西达尿苷和阿扎胞苷的固定剂量组合

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110927